The Lynx Group

In the Literature

Patients with triple-negative breast cancer (TNBC) have a high relapse rate and poor outcome after standard treatment. Capecitabine (Xeloda), a chemotherapy that has been used widely in the treatment of metastatic breast cancer, is a potential maintenance treatment option for the prevention of TNBC recurrence based on results of a recent study.
Read Article

Induction chemotherapy leads to remission in many patients with acute myeloid leukemia (AML) aged ≥60 years; however, the disease relapses in the majority of the patients, and the overall survival (OS) is poor. For patients who are not candidates for hematopoietic stem-cell transplant, effective maintenance treatments for AML are needed that can reduce the risk for relapse and improve OS, without causing unacceptable adverse events or compromising quality of life.
Read Article

Patients with advanced urothelial carcinoma and disease progression after treatment with platinum-based chemotherapy and PD-1 or PD-L1 inhibitors have limited treatment options. Enfortumab vedotin (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, demonstrated an objective response rate (ORR) in more than 40% of patients with advanced urothelial carcinoma who had progression after previous treatment.
Read Article

Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem-cell transplant (HSCT). The rate of GVHD is between 34% and 51% within 100 days of undergoing transplant.
Read Article

Chemotherapy is currently the standard of care for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC); however, some patients have disease that is refractory to chemotherapy.
Read Article

The overall mortality for lung cancer has declined in the United States, but little is known about the mortality trends by lung cancer subtype, because death certificates do not record this information. To address this limitation in the data collection, the Surveillance, Epidemiology, and End Results (SEER) program has linked mortality records to incident cancer cases in all cancer types.
Read Article

The safety and durability of responses to multitargeted inhibitors in thyroid cancer are at least partially limited by side effects. In all, 70% of patients with medullary thyroid cancer carry the RET mutation; RET fusions are rare in other types of thyroid cancer. The efficacy and safety of selective RET inhibition in patients with RET-altered thyroid cancer is unknown.
Read Article

The prognosis of older patients with acute myeloid leukemia (AML) has been poor, even after treatment with a hypomethylating agent. A previous phase 1b study of azacitidine (Vidaza) added to venetoclax (Venclexta) showed promising efficacy and duration of response in treatment-naïve patients with AML who were ineligible for chemotherapy.
Read Article

Patients with anemia and lower-risk myelodysplastic syndromes (MDS) in whom first-line erythropoiesis-stimulating agents (ESAs) are not effective generally become transfusion dependent. Luspatercept-aamt (Reblozyl), a recombinant fusion protein that binds transforming growth factor beta superfamily ligands to reduce SMAD2 and SMAD3 signaling, was approved by the FDA in November 2019 and has been studied in this patient population with promising results.

Read Article

The discontinuation of oral oncology medications before the full-month supply has been finished results in medication waste, leading to increased costs for patients and for payers. Split fills allow for a 14- to 16-day supply for oral oncology medications rather than a full 28- to 30-day supply. Researchers compared the discontinuation rates, patient-reported adverse events, estimated pharmacy costs, and potential waste in patients with pharmacy benefit designs that included a split-fill option with patients who did not have this option (Staskon FC, et al. J Oncol Pract. 2019;15:e856-e862).

Read Article

Page 1 of 13

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: